Another big license from Jun Shi. How does Tripley widen the sea road?

On the evening of May 5, the company issued a public announcement announcing that it had signed an exclusive license and commercialization Agreement with Dr. Reddy's Laboratory, in which it agreed to grant a license to Dr. Reddy's laboratory to develop and exclusively commercialize triprilimab inJ in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa. Dr Reddy's laboratory has the option to extend its licence to Australia and New Zealand and nine other countries.

According to the announcement, the signing of the license and commercialization agreement is an important practice in the company's continued expansion of its global commercialization network and will accelerate the development of Triprilimab and other products in overseas markets.

The inner market is in dire straits,
How did Tripley do?

As a representative of domestic PD-1, Triplelimab has been making steady progress in the crowded market.

In terms of indication expansion, according to Pharmacowisdom data, Triprilimab has been approved for a number of indications such as melanoma, nasopharyngeal carcinoma and urothelial carcinoma. Earlier in April, the FDA also approved triprilimab for the perioperative treatment of patients with operable non-small cell lung cancer.

However, in terms of global commercialization, although Monsil has conducted more than 30 clinical studies covering more than 15 indications for triprilimab, not many indications have been approved overseas, and none have even been approved by the FDA.

The domestic form of PD-1 can only be described as "internal roll." In addition to crowded tracks, constant "afterwaves" hit, and health insurance "slap", resulting in drug prices and difficult to recoup costs.

According to Junshi's 2022 annual report, the sales revenue of Triplelimab in the domestic market reached 736 million yuan, a year-on-year increase of 78.77%. However, by 2021, the cumulative R&D investment of Triplelimab has reached 3.679 billion yuan.

In other words, even breaking even is difficult for Tririprimab.

Thus, "going to sea" became the inevitable next step.

The road to sea is long and difficult,
Where does Tripley roll up to?

In March 2021, the company submitted a rolling FDA marketing application for triprilimab for the treatment of relapsed or metastatic nasopharyngeal carcinoma. But it was put on hold because of the pandemic.

In July 2022, Junshi Bio reapplied for listing. So far, triprilimab has received 2 breakthrough therapy approvals, 1 fast track approval, 1 priority Review approval and 5 orphan drug approvals from the FDA in the fields of mucosal melanoma, nasopharyngeal carcinoma, soft tissue sarcoma, esophageal cancer and small cell lung cancer.

In terms of strength, we can say that Triplelimab is absolutely reliable.

However, in the U.S. and Europe, the PD-1 will only get bigger. It's only gonna be harder to fight our way out of here.

So he turned and walked back to Southeast Asia.

In late March, Junsil issued an announcement granting Excellmab, a wholly-owned subsidiary of Conlixed BioTechnologies, an exclusive license to develop and commercialize triprilimab for intravenous use and other related rights in Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.

Just yesterday, a little over a month later, Junsil reached an agreement with Dr. Reddy's lab to expand triprilimab to Brazil, Mexico, Colombia, Argentina and other regions.

In this process, you reap a lot. Although we will only get a portion of the sales of triprilimab in these regions in the future, it may be more difficult to commercialize and distribute with full responsibility for Monash, which may not yield much in the end.

summary

The agreement is an important exercise in continuing to expand the global commercialisation network and will accelerate the introduction of other drugs to the sea, Junshi said. In fact, the road to triplelimab is all about "quality". Without good efficacy, who wants to pay? So at the end of the day, it's all about having a good "firstinclass" beyond business strategy.